CD19 and B-cell non-Hodgkin lymphoma: For instance, anti-CD-19/CD22 bispecific CAR-NK-92 cells incorporating a CD3ζ/CD137 signalling domain exhibited increased cytotoxicity against B cell lymphoma cells compared to anti-CD19 CAR-NK-92 cells alone (163).